Lutetium (177Lu) oxodotreotide
Lutetium (177Lu) oxodotreotide
Lutetium (177Lu) oxodotreotide (pronunciation: loo-TEE-shee-um ox-oh-doh-TREE-oh-tide), also known as 177Lu-DOTATATE, is a radiopharmaceutical used in the treatment of certain types of neuroendocrine tumors. It is a type of peptide receptor radionuclide therapy (PRRT) that combines a somatostatin analogue with a radioactive isotope, lutetium-177.
Etymology
The name "Lutetium (177Lu) oxodotreotide" is derived from the elements that make up the compound. "Lutetium" is named after Lutetia, the Latin name for Paris, where the element was discovered. The "177Lu" refers to the specific isotope of lutetium used. "Oxodotreotide" is a type of somatostatin analogue, and the name is derived from the chemical structure of the compound.
Usage
Lutetium (177Lu) oxodotreotide is used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. It works by binding to somatostatin receptors on the surface of the tumor cells, allowing the radioactive lutetium-177 to deliver targeted radiation therapy.
Related Terms
- Radiopharmaceutical
- Neuroendocrine tumor
- Peptide receptor radionuclide therapy
- Somatostatin analogue
- Gastroenteropancreatic neuroendocrine tumors
See Also
External links
- Medical encyclopedia article on Lutetium (177Lu) oxodotreotide
- Wikipedia's article - Lutetium (177Lu) oxodotreotide
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski